Want to see ELMD full AI Analyst Report?
ELMD Stock Chart & Stats
$24.83
$0.65(2.15%)
At close: 4:00 PM EST
$24.83
$0.65(2.15%)
Day’s Range― - ―
52-Week Range$17.73 - $47.40
Previous CloseN/A
Volume34.94K
Average Volume (3M)111.24K
Market Cap
$348.59M
Enterprise Value$185.46
Total Cash (Recent Filing)$16.98M
Total Debt (Recent Filing)$81.00K
Price to Earnings (P/E)34.5
Beta0.76
Next Earnings
Sep 01, 2026EPS Estimate
0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.22
Shares Outstanding8,280,064
10 Day Avg. Volume177,277
30 Day Avg. Volume111,241
Financial Highlights & Ratios
PEG Ratio0.49
Price to Book (P/B)4.24
Price to Sales (P/S)2.86
P/FCF Ratio16.53
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$38.00Price Target Upside53.04% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)1.41
Revenue Forecast (FY)$82.97M
Bulls Say, Bears Say
Bulls Say
High And Expanding MarginsSustained very high gross margins and improving net margins indicate durable product-level economics and pricing power for SmartVest. This margin base supports reinvestment, funds expansion of sales/fulfillment, and creates a cushion against reimbursement pressure over the next several quarters.
Conservative, Debt-free Balance SheetA debt-free capital structure and healthy equity base provide financial flexibility to fund sales expansion, product support, and potential buybacks without reliance on external financing. This lowers solvency risk and preserves optionality through 2–6 months of execution cycles.
Operational Execution (ePrescribe & Manufacturing)Adoption of ePrescribe and manufacturing optimization materially reduce fulfillment friction and working-capital swings, improving order throughput and patient conversion. These durable operational improvements should sustain higher capacity and shorten monetization timelines for prescriptions.
Bears Say
Dependence On Sales Rep RampGrowth is materially tied to adding and ramping field reps; execution risk in hiring, retention, or slower-than-expected productivity can delay revenue capture. Over the medium term, missed rep productivity targets would constrain scalable penetration of under‑served bronchiectasis patients.
Slowing Recent Revenue MomentumA deceleration in trailing revenue growth versus historical trends suggests market penetration or conversion headwinds. If growth reverts to lower TTM rates, operating leverage gains could plateau and the company may need outsized investment to reaccelerate adoption.
Historical Cash-flow VolatilityPrior periods of negative operating and free cash flow highlight sensitivity to working-capital and investment swings. This historical volatility means cash conversion can deteriorate in a downturn or during expansion, potentially constraining reinvestment or capital returns.
Electromed News
ELMD FAQ
What was Electromed’s price range in the past 12 months?
Electromed lowest stock price was $17.73 and its highest was $47.40 in the past 12 months.
What is Electromed’s market cap?
Electromed’s market cap is $348.59M.
When is Electromed’s upcoming earnings report date?
Electromed’s upcoming earnings report date is Sep 01, 2026 which is in 43 days.
How were Electromed’s earnings last quarter?
Electromed released its earnings results on May 12, 2026. The company reported $0.35 earnings per share for the quarter, beating the consensus estimate of $0.25 by $0.1.
Is Electromed overvalued?
According to Wall Street analysts Electromed’s price is currently Undervalued.
Does Electromed pay dividends?
Electromed does not currently pay dividends.
What is Electromed’s EPS estimate?
Electromed’s EPS estimate is 0.32.
How many shares outstanding does Electromed have?
Electromed has 8,280,064 shares outstanding.
What happened to Electromed’s price movement after its last earnings report?
Electromed reported an EPS of $0.35 in its last earnings report, beating expectations of $0.25. Following the earnings report the stock price went up 25.11%.
Which hedge fund is a major shareholder of Electromed?
Currently, no hedge funds are holding shares in ELMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Electromed Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$38.00 (53.04% Upside)
$38.00 (53.04% Upside)
Blogger Sentiment
Bullish
ELMD Sentiment 70%
Sector Average 66%
Sector Average 66%
Insider Transactions
Sold Shares
Worth $2.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.4%
Last 30 Days ▲ 19.5%
Last 30 Days ▲ 19.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
125.73%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
13.39%
Trailing 12-Months
Company Description
Electromed
Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy, muscular dystrophies, amyotrophic lateral sclerosis, and post-surgical complications; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. It markets its products to physicians, health care providers, and directly to patients. Electromed, Inc. was incorporated in 1992 and is headquartered in New Prague, Minnesota.
ELMD Stock 12 Month Forecast
Average Price Target
$38.00
▲(53.04% Upside)
Technical Analysis
Ownership Overview
7.17% Insiders
10.32% Mutual Funds
0.12% Other Institutional Investors
72.99% Public Companies and
Individual Investors